117 related articles for article (PubMed ID: 2334171)
1. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Shirasaka T; Fujita F; Fujita M; Fukushima M; Taguchi T; Fujii S
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1871-6. PubMed ID: 2393305
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
[TBL] [Abstract][Full Text] [Related]
4. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Fujii S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Fujita F; Fujita M; Inaba H; Taguchi T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):223-8. PubMed ID: 8434959
[TBL] [Abstract][Full Text] [Related]
6. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
7. The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo.
Murata R; Shibamoto Y; Miyauchi S; Hirohashi M; Takagi T; Sasai K; Oya N; Hiraoka M
Br J Cancer Suppl; 1996 Jul; 27():S114-6. PubMed ID: 8763861
[TBL] [Abstract][Full Text] [Related]
8. Mutagenic and clastogenic properties of (3-[3-(6-benzoyloxy-3-cyano-2- pyridyloxycarbonyl) benzoyl]-1-ethoxymethyl-5-fluorouracil) (BOF-A2), a new 5-fluorouracil derivative with anti-tumour activity.
Shibahara T; Kaneko E; Itoh T; Awogi T; Tsushimoto G; Takahashi N; Marshall RR; Kirkland DJ
J Toxicol Sci; 1993 Aug; 18 Suppl 3():11-9. PubMed ID: 8258847
[TBL] [Abstract][Full Text] [Related]
9. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Miyauchi S; Imaoka T; Okada T; Motoyama M; Kawaguchi T; Akiyama H; Odomi M
Jpn J Pharmacol; 1996 Feb; 70(2):139-48. PubMed ID: 8866751
[TBL] [Abstract][Full Text] [Related]
10. [Development of fluorinated pyrimidines in Japan].
Taguchi T
Gan To Kagaku Ryoho; 1993 Jan; 20(1):10-8. PubMed ID: 8422172
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Miyauchi S; Imaoka T; Utsunomiya T; Hayashi K; Kubo M; Kawaguchi T; Matsui Y
Jpn J Cancer Res; 1994 Jun; 85(6):665-8. PubMed ID: 8063621
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma.
Yoneda K; Yamamoto T; Ueta E; Osaki T
Cancer Lett; 1999 Mar; 137(1):17-25. PubMed ID: 10376790
[TBL] [Abstract][Full Text] [Related]
13. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
Fujita F; Fujita M; Sakamoto Y; Taguchi T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):215-21. PubMed ID: 8382036
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil.
Spector T; Cao S; Rustum YM; Harrington JA; Porter DJ
Cancer Res; 1995 Mar; 55(6):1239-41. PubMed ID: 7882316
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Okayasu T; Sugiyama K; Miyauchi S
Jpn J Cancer Res; 1994 Jan; 85(1):101-5. PubMed ID: 8106287
[TBL] [Abstract][Full Text] [Related]
17. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside analogs. 14. The synthesis of antitumor activity in mice of molecular combinations of 5-fluorouracil and N-(2-Chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain.
McElhinney RS; McCormick JE; Bibby MC; Double JA; Radacic M; Dumont P
J Med Chem; 1996 Mar; 39(7):1403-12. PubMed ID: 8691470
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of 1-phthalidyl-5-fluorouracil (PH-FU)].
Fujita H; Takao A; Okamoto M; Kimura K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2199-207. PubMed ID: 3717964
[TBL] [Abstract][Full Text] [Related]
20. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
